As a result of Charles River’s continued commitment to emerging drug discovery technologies, a strategic collaboration has been established with caprotec bioanalytics, GmbH, to offer their proprietary protein capture technology for phenotypic screening target deconvolution.
During the finalization of the OECD 443 guideline, Extended One-generation Reproductive Toxicity Study (EOGRTS), scientists at our facilities in Den Bosch, Lyon and Ashland were asked to work on the implementation of this study type and to harmonize the study designs at the sites.
The Single Mouse Trial (SMT) format for in vivo patient-derived xenograft (PDX) studies addresses the need for more cost-effective compound testing in the larger, more diverse tumor populations that can be targeted using our vast portfolio of highly characterized models.
On May 14, 2016, Charles River sponsored Great Strides®, a walk supporting the Cystic Fibrosis Foundation. The event brought more than 950 participants to the Cleveland Zoo and raised more than $270,000 to support the search for a cure.
In addition to an exhibit, Charles River scientists presented three posters and moderated a presentation during this year's conference.
Continuous health surveillance is a critical task in resident animal colony management. Rapid, trusted results provide the information you need to make go/no-go decisions regarding contamination and to avoid the consequences of a biosecurity breach. Charles River has always provided timely, reliable data on every health monitoring sample we process. Our recent laboratory improvements will deliver even greater efficiency and value to our clients.
Charles River’s commitment to the 3Rs continues with Curiox miniaturized assays that can be coupled with Luminex® technology. Multiplex panels currently being developed and offered by Charles River include the simultaneous measurement of cytokines, chemokines, hormones and metabolic biomarkers, bone markers, cardiac and muscle injury markers, and renal toxicity biomarkers.
PET imaging is an important translational tool for the assessment of target engagement and disease progression in animal models and clinical trials.
During the last year, the move to replace the rabbit pyrogen test whenever possible has increased, especially in Europe. Companies should start to actively discuss this topic internally in order to determine the path forward.
Charles River now provides FcγR-binding assays with HTRF readout for FcγRI, -II, -III and FcγRn. These assays are used to measure the binding of therapeutic mAbs to Fcγ-receptors and are suitable for assessing biosimilarity.